Viyash Scientific Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics and Market Context

As of 13 Aug 2026, Viyash Scientific Ltd trades at ₹262.95, marginally up 0.57% from the previous close of ₹261.45. The stock has demonstrated strong resilience with a year-to-date return of 26.33%, significantly outperforming the Sensex’s negative 8.51% return over the same period. Over the past year, the stock has surged 50.90%, while the benchmark index declined by 2.83%. This outperformance extends over the medium term as well, with a three-year return of 186.97% compared to Sensex’s 19.36%, underscoring the company’s growth trajectory despite broader market volatility.

Viyash Scientific’s 52-week trading range spans ₹167.50 to ₹297.90, indicating a relatively wide price band but with recent price action consolidating near the upper end. The day’s trading range between ₹258.60 and ₹267.85 suggests steady investor interest and moderate volatility.

Shift in Valuation Grade: From Expensive to Fair

The company’s valuation grade has been upgraded from “Expensive” to “Fair” as of 11 May 2026, reflecting a recalibration of key multiples. The price-to-earnings (P/E) ratio stands at 47.89, which, while elevated, is more reasonable compared to previous levels and relative to certain peers. The price-to-book value (P/BV) ratio is 3.95, indicating a premium but within a fair valuation range for a growth-oriented pharmaceutical firm.

Enterprise value to EBITDA (EV/EBITDA) is 16.46, a figure that suggests the stock is priced with growth expectations but is less stretched than some competitors. For context, Gland Pharma, a peer, trades at an EV/EBITDA of 25.32 and is rated as “Expensive,” while Sai Life and Wockhardt are classified as “Very Expensive” with EV/EBITDA multiples of 47.48 and 40.92 respectively.

The PEG ratio of 1.10 further supports the notion that Viyash Scientific’s valuation is aligned with its earnings growth prospects, offering a more balanced risk-reward profile compared to peers with lower PEG ratios but higher absolute multiples.

Comparative Analysis with Industry Peers

Within the Pharmaceuticals & Biotechnology sector, Viyash Scientific’s valuation stands out as more reasonable when juxtaposed with several large-cap and mid-cap peers. For instance, Emcure Pharma trades at a P/E of 36.75 but is still considered “Expensive,” while Rubicon Research’s P/E ratio exceeds 110, categorising it as “Very Expensive.” Pfizer, a global giant, also holds a “Very Expensive” tag with a P/E of 29.77 but a notably higher PEG ratio of 2.07, indicating expectations of slower growth relative to price.

Return on capital employed (ROCE) for Viyash Scientific is 13.36%, reflecting efficient utilisation of capital in generating earnings before interest and taxes. Return on equity (ROE) is more modest at 7.11%, suggesting room for improvement in shareholder returns but consistent with a company in a growth phase investing in expansion and R&D.

Enterprise value to capital employed (EV/CE) and EV to sales ratios of 3.74 and 3.28 respectively further reinforce the fair valuation narrative, as these multiples are moderate compared to sector averages, signalling that the market is pricing in growth without excessive exuberance.

Stock Performance Versus Sensex Benchmarks

Viyash Scientific’s stock performance relative to the Sensex over various time horizons highlights its strong momentum. Despite a slight pullback in the short term with a one-week return of -3.87% and one-month return of -5.53%, the stock’s long-term trajectory remains robust. The five-year return of -1.24% contrasts with the Sensex’s 42.16%, but this is largely due to earlier periods of consolidation and sector-specific challenges. Over ten years, the stock’s return of 173.11% nearly matches the Sensex’s 176.94%, underscoring sustained value creation over the long haul.

These figures suggest that investors with a medium to long-term horizon have been rewarded handsomely, while short-term volatility may present tactical entry points for discerning buyers.

Outlook and Investment Considerations

With the valuation grade upgrade to “Hold” from “Sell” and a Mojo Score of 67.0, Viyash Scientific is positioned as a stock warranting cautious optimism. The company’s small-cap status implies higher volatility and risk, but also potential for outsized returns if growth catalysts materialise.

Investors should weigh the company’s improving valuation metrics against sector headwinds such as regulatory pressures, pricing competition, and R&D expenditure. The fair valuation grade suggests that the market has adjusted expectations to a more realistic level, potentially reducing downside risk compared to prior periods when the stock was deemed expensive.

Conclusion: Valuation Attractiveness Enhanced but Caution Advised

Viyash Scientific Ltd’s transition from an expensive to a fair valuation grade marks a significant development for investors analysing the Pharmaceuticals & Biotechnology sector. The company’s improved multiples, combined with strong relative stock performance and a positive Mojo Grade upgrade to “Hold,” suggest that the stock is now more attractively priced than in recent quarters.

However, the relatively high P/E ratio near 48 and moderate ROE indicate that while growth prospects are promising, investors should remain vigilant about execution risks and sector dynamics. The stock’s small-cap nature adds an element of volatility, making it suitable for investors with a higher risk tolerance and a medium to long-term investment horizon.

Overall, Viyash Scientific presents a compelling case for inclusion in a diversified portfolio focused on pharmaceutical innovation and growth, provided investors carefully monitor valuation trends and sector developments.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today